RainDance Technologies Appoints Kathy Ordonez as CEO
News Jul 20, 2016
RainDance Technologies, Inc., has announced the appointment of Kathy Ordoñez as Chief Executive Officer. She continues in her current role as Chairman of the Board of Directors. Former CEO Roopom Banerjee has left the Company to pursue other opportunities.
After joining the Board of RainDance in July 2014, Ms. Ordoñez established and led the Science and Innovation Committee for the Board and was named the Company’s Chairman of the Board in September 2015. She has subsequently provided guidance to the Company’s management team and has worked closely with the Company’s investors while leading the Company’s product strategy and development efforts.
“Kathy Ordoñez is highly respected in the life sciences and diagnostics industry,” said Michael Hunkapiller, Ph.D., a Board Director at RainDance Technologies. “Kathy has brought new focus to RainDance over the past two years, and our board and investors believe her relationship with the team, her creative mindset, and deep industry experience will advance the adoption and reach of RainDance’s products and technologies.”
Ms. Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. As Senior Vice President at Quest Diagnostics, she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading producer of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.
“It is a privilege to lead the RainDance team, whose members invented and developed key biological applications of droplet technology,” said Ms. Ordoñez. “I look forward to building on my relationships with RainDance team members and our business and research partners to launch new products incorporating these innovations over the coming months.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE